^
Association details:
| Biomarker: | ACLY underexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
Published date:
01/04/2022
Excerpt:
We found that sorafenib treatment was effective in 32.3% of patients in the group with low expression of ACLY, whereas it was only 14.3% effective in the group with high expression of ACLY (Table 2)….The Kaplan-Meier survival curve showed that the survival of patients with high expression of ACLY was shorter than that of patients with low expression of ACLY (P < 0.05) (Figure 2).
DOI:
10.7150/jca.52778
